Jazz Pharmaceuticals (JAZZ) Misses Q1 EPS by 15c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Jazz Pharmaceuticals (JAZZ) Misses Q1 EPS by 15c

Cantor Fitzgerald Loweres PT to $165 for Jazz Pharmaceuticals (JAZZ) Following 1Q15 EPS Miss

May 11, 2015 7:52 AM EDT

Cantor Fitzgerald reiterates their Hold rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and lowered the price target to $165.00 (from $175.00) following a 1Q15 EPS miss. JAZZ reported in-line revenue of $309M, but missed the adjusted diluted EPS with $1.99 (vs. $2.14 estimates). Cantor Fitzgerald said that they... More

Guggenheim Securities Remains Bullish in Wake of Jazz Pharmaceuticals (JAZZ) 1Q15 EPS Miss

May 8, 2015 8:46 AM EDT

Guggenheim Securities maintains a Buy status on Jazz Pharmaceuticals, PLC (NASDAQ: JAZZ), with a price target set at $210. This follows an EPS miss from JAZZ in 1Q15. JAZZ reported 1Q15 adjusted diluted EPS of $1.99. This came in $0.15 lower than consensus and $0.18 lower than Guggenheim estimated. Guggenheim believes that... More